Allergy Diagnostics And Therapeutics Market Summary

The global allergy diagnostics and therapeutics market size was estimated at USD 34.42 billion in 2024 and is projected to reach USD 78.00 billion by 2033, growing at a CAGR of 9.7% from 2025 to 2033. This steady growth reflects the increasing burden of allergic diseases worldwide and the rising demand for accurate diagnostic tools and effective treatment options. Some of the major factors driving the market are the rising incidence of allergies across all age groups, continuous advancements in diagnostic and therapeutic technologies, the launch of innovative products, and the high adoption of immunotherapy drugs that offer long-term disease management and improved patient outcomes.

In November 2022, the Global Allergy and Airways Patient Platform reported that approximately 30–40% of people today have one or more allergies, and the number of individuals affected has been increasing consistently over the past 20 years. This growing prevalence highlights allergies as a significant global public health concern. Furthermore, changing lifestyles, urbanization, dietary habits, and increasing levels of air pollution are some of the key factors contributing to the rising incidence of allergic conditions such as asthma, allergic rhinitis, food allergies, and skin allergies. The introduction of therapeutically advanced drugs, particularly immunotherapy solutions that address unmet patient needs by targeting the underlying causes of allergies rather than only symptoms, is expected to boost market growth over the forecast period.

Key Market Trends & Insights

• The North America allergy diagnostics and therapeutics market dominated the global market and accounted for the largest revenue share of 36.53% in 2024, supported by strong healthcare infrastructure, high awareness levels, and early adoption of advanced therapies.
• The U.S. led the North American market and held the largest revenue share in 2024, driven by significant research investments, favorable reimbursement policies, and widespread use of allergy testing and immunotherapy treatments.
• By type, the therapeutics segment dominated the global market and diagnostics accounted for the largest revenue share of 81.46% in 2024, reflecting strong demand for effective treatment options alongside reliable diagnostic solutions.
• By allergen type, the inhaled segment held the largest revenue share of 49.77% in 2024, due to the high prevalence of respiratory allergies caused by pollen, dust mites, and air pollutants.
• By test type, the in vivo test segment held the largest revenue share of 51.92% in 2024, owing to its accuracy and widespread clinical usage.

Order a free sample PDF of the Allergy Diagnostics And Therapeutics Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2024 Market Size: USD 34.42 Billion
• 2033 Projected Market Size: USD 78.00 Billion
• CAGR (2025-2033): 9.7%
• North America: Largest market in 2024

Key Companies & Market Share Insights

The allergy diagnostics & therapeutics industry is highly competitive and market players are involved in activities such as strategic collaborations, new product launches, acquisitions, technological advancements, and regional expansion.

Key Players

• R-Biopharm AG
• R-Biopharm AG
• DASIT Group SPA
• EUROIMMUN Medizinische Labordiagnostika AG (PerkinElmer, Inc.)
• GROUP GmbH
• bioMérieux
• Siemens Healthcare GmbH
• Stallergenes Greer
• HYCOR Biomedical
• Minaris Medical America, Inc.
• Omega Diagnostics Group PLC
• Lincoln Diagnostics, Inc.
• HOB Biotech Group Corp., Ltd.
• Danaher
• Alcon
• AbbVie, Inc.
• Sanofi
• Allergy Therapeutics
• Pfizer, Inc.
• Teva Pharmaceutical Industries Ltd.
• GSK plc
• Sun Pharmaceutical Industries Ltd
• Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Astellas Pharma Inc.
• Epigenomics AG

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The allergy diagnostics and therapeutics market is witnessing robust growth driven by the rising prevalence of allergic disorders, environmental changes, and continuous advancements in medical technologies. Increasing awareness, early diagnosis, and the growing adoption of immunotherapy are improving long-term disease management. North America, led by the U.S., remains a key revenue contributor due to strong healthcare systems and innovation. Dominance of inhaled allergens and in vivo testing reflects current clinical practices. Overall, the market is expected to expand steadily, supported by innovation, patient-centric therapies, and increasing global healthcare demand.